SLC1A2 and neuropathic pain: These findings are supported by previous work which shows that (1) intrathecal delivery of CTX produced antinociceptive effect in both thermal and mechanical nociception tests in a neuropathic pain model [4], (2) gene transfer of GLT-1 into spinal cord astrocytes by recombinant adenoviruses attenuated inflammatory and neuropathic pain, probably via prevention of central sensitization [5], and (3) intrathecal injection of GLT-1 antisense oligodeoxynucleotides reversed the antinociceptive effects of 1-week CTX treatment in a neuropathic pain model [4].